Chiba Refractory Schizophrenia Treatment-LAI study

Trial Profile

Chiba Refractory Schizophrenia Treatment-LAI study

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2016

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms CREST
  • Most Recent Events

    • 03 May 2016 Status changed from active, no longer recruiting to completed.
    • 25 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top